Larry M. Weisenthal MD, PhD
Weisenthal Cancer Group; Associate Clinical Professor, U Cal Irvine Medical School
Huntington Beach, CA
Professional summary
I have a 22 year full time experience in providing cell culture drug resistance testing as a clinical service to oncologists and patients, following 8 years of previous research experience. I am an early member of an emerging new medical specialty, which I refer to as Laboratory Oncology. The function of the laboratory oncologist is to utilize available forms of laboratory testing of tumor biopsies to best individualize (or "personalize") cancer treatment with drugs, radiation, and/or surgery. These forms of laboratory testing are based on multiple approaches, including traditional anatomic pathology, molecular genetics, and cell biology (typically through the application of cell culture methodologies). The importance of Laboratory Oncology is that there is an exploding growth in the number of anticancer drugs, which tend to be of only partial and unpredictable efficacy, which are often toxic, and which are extremely expensive. There is a huge need for existing and improved methodologies to best match treatment to patient.
Specialties and Interests
-
Medical Oncology,
-
Internal Medicine
Contact
Office Phone
714-596-2100
Websites
- http://weisenthal.org (general information about cell culture testing of fresh human tumors)
- http://weisenthalcancer.com (clinical laboratory website)
- http://CancerTest.org (international blog for scientists in field of laboratory testing of fresh human tumor biopsy specimens)
Education
Universities
University of Michigan
Doctor of Medicine, Medicine
University of Michigan
Doctor of Philosophy, research doctorate, Pharmacology
Postgraduate Training
National Cancer Institute
Licenses/Certifications
Medical Oncology
Internal Medicine
Mentors
Marc E Lippman MD
Raymond W Ruddon MD PhD
Experience
Associate Clinical Professor of Medicine (Voluntary faculty)
Publications
Articles
"Antineoplastic activity of idazoxan hydrochloride."
"Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood."
"Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question."
"Controversy over paper on chemosensitivity testing."
"Clinical correlations for cell culture assays based on the concept of total tumor cell kill."
"2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms."
"Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays."
"Antineoplastic drug screening belongs in the laboratory, not in the clinic."
"Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill."
"Effect of prior chemotherapy on biologic response modifier activity."
Lectures and Presentations
Long term survival in metastatic colon cancer predicted by 5FU activity in MTT assay
Introduction to new cancer diagnostics: targeting "targeted" drugs in cancer treatment
Activity of cisplatin in triple-negative breast cancer in comparison to other cancer types in fresh tumor cell culture assay using a cell death endpoint
Cell culture assays for traditional and "targeted" therapy in cancer
Targeting "targeted" drug therapy in cancer
Antivascular activity of lapatinib and bevacizumab in primary microcluster culture of breast cancer and other neoplasms
Individualized tumor response testing with cell culture assays
Functional profiling with cell culture assays in cancer therapy
Individualized pharmacotherapy with cell culture assays
Functional profiling for traditional and targeted antineoplastic drugs
Disclosures
Larry M. Weisenthal MD, PhD has nothing to disclose
Tokens of Appreciation
- 1 token received
- What are Tokens of Appreciation?
A Token of Appreciation is a way of acknowledging another member for their contributions to Medpedia. You have 5 Tokens to give per week.
